Thermo Fisher Scientific Inc. (TMO) - NYSE
  • Thu, May 19, 2:50 AM
    • The World Health Organization is sounding off another Zika alarm, stating the virus is likely to spread to parts of Europe this summer, although the likelihood of an outbreak is low to moderate.
    • Areas most at risk include the Black Sea coast of Russia and Georgia and the island of Madeira.
    • Countries with a moderate risk include France, Spain, Italy and Greece, while the threat in the U.K. is low.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Thu, May 19, 2:50 AM | 15 Comments
  • Wed, May 18, 4:37 PM
    • Thermo Fisher Scientific (NYSE:TMO) declares $0.15/share quarterly dividend, in line with previous.
    • Forward yield 0.4%
    • Payable July 15; for shareholders of record June 15; ex-div June 13.
    | Wed, May 18, 4:37 PM
  • Wed, May 18, 2:44 AM
    • More than three months after President Obama asked for $1.8B in emergency funds to combat the Zika virus, the Senate took its first step to approve the request by passing a compromise $1.1B measure.
    • At the same time, the White House issued a veto threat against a House Republicans' bill that would provide only $622M, a figure the White House called "woefully inadequate" to fight the rapidly spreading disease.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Wed, May 18, 2:44 AM | 22 Comments
  • Mon, May 16, 6:15 PM
    • Thermo Fisher Scientific's (NYSE:TMO) Life Technologies unit settles its patent infringement dispute with Enzo Biochem's (NYSE:ENZ) Enzo Life Sciences subsidiary by agreeing to pay $35M to Enzo. The payment settles the fourth of 11 total suits against various companies filed by Enzo alleging infringement on U.S. Patents Nos. 6,992,180 and 7,064,197.
    | Mon, May 16, 6:15 PM
  • Wed, May 4, 12:32 PM
    • Glenview Capital's Larry Robbins has nothing "immediately actionable," but the Ira Sohn regular is still a bull on CBS (CBS +1.8%), Anthem (ANTH -8.4%), Thermo Fisher (TMO +0.1%), Flextronics (FLEX -0.9%), and Labcorp (LH -0.7%).
    | Wed, May 4, 12:32 PM | 1 Comment
  • Thu, Apr. 28, 7:25 AM
    • Thermo Fisher Scientific (NYSE:TMO) Q1 Results ($M): Total Revenues: 4,294.8 (+9.6%); Life Sciences Solutions: 1,133.0 (+11.1%); Analytical Instruments: 759.3 (+4.4%); Specialty Diagnostics: 854.6 (+8.8%); Lab Products & Services: 1,724.6 (+14.0%).
    • Net Income: 402.2 (+4.4%); Non-GAAP Net Income: 717.1 (+9.4%); EPS: 1.01 (+5.2%); Non-GAAP EPS: 1.80 (+10.4%); CF Ops: 289.1 (+261.4%).
    • 2016 Guidance: Revenues: $17.86B - 18.04B from $17.36B - 17.56B; Non-GAAP EPS: $8.05 - 8.19 from $7.80 - 7.96.
    | Thu, Apr. 28, 7:25 AM
  • Thu, Apr. 28, 6:03 AM
    • Thermo Fisher Scientific (NYSE:TMO): Q1 EPS of $1.80 beats by $0.06.
    • Revenue of $4.29B (+9.4% Y/Y) beats by $180M.
    • Press Release
    | Thu, Apr. 28, 6:03 AM
  • Wed, Apr. 27, 5:30 PM
  • Wed, Apr. 27, 4:18 PM
    • Looking in the rear view mirror, author and New York Time columnist Randall Stross says the red flags were numerous surrounding discredited diagnostics firm Theranos and its relentlessly self-promoting chief Elizabeth Holmes.
    • First, the company failed to elicit investments from the major Silicon Valley venture capital players despite numerous pitches/presentations. Professor Stross says it was turned down twice by GV (formerly Google Ventures) due to the apparent lack of substance (technical data) backing up its claims.
    • Second, the company refused to publish in peer-reviewed journals, a tried-and-true way to credential the technology.
    • Third, the make-up of the board was puzzling, since no member had experience in the diagnostics industry. Celebrity members, in this case former Secretary of State George Schultz and former National Security Advisor and Secretary of State Henry Kissinger, reinforced the perception that the constituency was for show instead of advancing the business.
    • At least Ms. Holmes is famous, sporting the covers of Fortune, Forbes, Inc., and T: The New York Times Style Magazine. Maybe Rolling Stone is next.
    • Diagnostics-related tickers: (NYSE:ABT)(OTCQX:RHHBY)(NYSE:TMO)
    | Wed, Apr. 27, 4:18 PM | 7 Comments
  • Thu, Apr. 14, 2:43 AM
    • U.S. health authorities have finally concluded that infection with the Zika virus in pregnant women is a cause of birth defects and other severe brain abnormalities in babies.
    • "There isn't any doubt that Zika causes microcephaly," said Tom Frieden, director of the U.S. Centers for Disease Control and Prevention.
    • The mosquito-born disease was assumed to be responsible for the alarming rise in birth defects among the Zika-hit areas of Brazil, but it had not been declared as the definitive cause until now.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Thu, Apr. 14, 2:43 AM | 13 Comments
  • Tue, Apr. 12, 2:36 AM
    • Dr. Anne Schuchat, a deputy director of the Centers for Disease Control and Prevention, told reporters the type of mosquito in which the virus is carried is present in a wider number of U.S. states, calling the revelation "scarier than we thought."
    • Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, announced at a White House briefing that the first Zika vaccine candidate should be available in September.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Tue, Apr. 12, 2:36 AM | 14 Comments
  • Thu, Apr. 7, 4:39 PM
    • Rumors doubting upstart blood tester Theranos' technology may be bit premature. The company recently hosted three scientific review sessions with leading experts who were invited to review its proprietary technologies with full access to its systems, devices and data. The group reviewed development and validation reports for tests performed on small volume samples, including finger-sticks, using Theranos' gear for a range of assays, including those chosen by the experts. They appear to have been favorably impressed.
    • Co-chair of the company's Scientific and Medical Advisory Board David Helfet, M.D., director of the Orthopedic Trauma Service, Hospital for Special Surgery and New York-Presbyterian Hospital says, "It is clear that Theranos has done what people thought was impossible. Theranos invited groups of independent experts in the fields of pathology and laboratory medicine and literally took the lid off of the box. Experts were shown Theranos' technology, met with Theranos scientists and had access to any data. Theranos' technology is a ground-breaking feat of science and engineering, making it possible to accurately analyze micro amounts of blood for the same tests routinely done today with traditional venipuncture."
    • After the three sessions, the company added eight prominent laboratory and medical experts to its Scientific and Medical Advisory Board. The group will advise company management and internal teams regarding the full integration of its technology into routine clinical practice. Those with laboratory management expertise will assist the company in inspecting its own labs and will help clinical lab directors implement best practices in their operations.
    • Say what you will about the company and its "black box" technology, but it would not be possible to engage a large group of experts without technical credibility.
    • Clinical diagnostics-related tickers: (NYSE:ABT)(OTCQX:RHHBY)(NYSE:TMO)
    | Thu, Apr. 7, 4:39 PM | 2 Comments
  • Tue, Apr. 5, 7:05 AM
    | Tue, Apr. 5, 7:05 AM
  • Thu, Mar. 31, 3:07 AM
    • Two mosquito species that carry the dangerous Zika virus may inhabit a wider range of North America than previously thought.
    • A new study published in the New England Journal of Medicine shows the potential range of the Aedes aegypti mosquito blanketing the southern U.S. and reaching as far north as San Francisco, Kansas City, and NYC.
    • The likely extent of another Zika-carrying mosquito species, Aedes albopictus, stretches across the Southwest and covers most of the eastern U.S., including northern New England, according to a study by the CDC.
    • Related tickers: SNY, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX
    | Thu, Mar. 31, 3:07 AM | 11 Comments
  • Mon, Mar. 28, 6:45 PM
    • With Affymetrix (AFFX -5.6%) spurning its offer in favor of an existing bid from Thermo Fisher, Origin Technologies -- the former Affymetrix execs trying to private the company -- has withdrawn its $17/share cash offer.
    • Affymetrix earlier said it would stick with a $14/share bid from Thermo Fisher (TMO -0.4%), which it considered less risky overall in case of a financing failure.
    • “We disagree with Affymetrix’ assessment of the perceived risks of our proposal," says Origin President Wei Zhou. "It is an unfortunate outcome.”
    • Origin said it received an "unrealistic demand" on Friday evening to put hundreds of millions of dollars in a U.S. escrow account by today. The company says it looks forward to work on genomics at Centrillion Technologies.
    • Affymetrix shareholders are set to vote Thursday on the Thermo Fisher offer.
    • After hours: AFFX -0.8%; TMO flat.
    • Update: TMO completed its acquisition of Affymetrix on March 31.
    | Mon, Mar. 28, 6:45 PM | 1 Comment
  • Tue, Mar. 22, 5:29 PM
    • Newly-formed Origin Technologies is now offering $17/share in cash for Affymetrix (NASDAQ:AFFX), up from a prior $16.10/share. Origin has also upped the size of its reverse termination fee to $100M, and reiterated its willingness to "include a 'hell or high water' provision in the merger agreement obligating itself to take any and all actions required to obtain regulatory approvals, in the event they are required."
    • The new bid comes shortly after Affymetrix said it's standing by a $14/share deal to sell to Thermo Fisher (NYSE:TMO), while declaring Origin to be a "shell entity with no assets of which Affymetrix is aware."
    • AFFX +4.4% after hours to $15.00.
    • Update: The company's board determined that Origin's new offer could be reasonably expected to lead to a Superior Proposal as defined in its merger agreement with Thermo Fisher. Accordingly, the Special Meeting of Stockholders scheduled for tomorrow will be convened and immediately adjourned without a vote. The meeting will reconvene on March 31 in order for the company to thoroughly evaluate Origin's proposal.
    • Update: The company will engage in discussions with Origin regarding its $17 per share bid. Key deliverables: draft of merger agreement and other transaction documents, copies of funding and financing documents and details on Origin's plans to obtain regulatory approvals. The board continues to recommend that stockholders back the merger with Thermo Fisher since there are no assurances of a positive outcome from discussions with Origin.
    | Tue, Mar. 22, 5:29 PM
Company Description
Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. The company operates its business through four segments: Analytical Technologies, Specialty Diagnostics, Life Sciences... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States